Cited by 68Bipolar Disorder and TreatmentTreatment of Major DepressionSchizophrenia research and treatment

Treatment of mixed bipolar states

Open access
Fountoulakis, Konstantinos N., Kontis, Dimitrios, Gonda, Xenia, Siamouli, Melina, Yatham, Lakshmi N.·2012·The International Journal of Neuropsychopharmacology

Abstract

Mixed bipolar states are associated with more severe symptoms and outcome. Our aim is to review the literature examining their treatment. We conducted a literature search of randomized clinical studies and post-hoc analyses on mixed bipolar states' treatment. Remarkably, there is only one double-blind, placebo-controlled trial, recruiting a mixed episode cohort, and one post-hoc analysis of this trial, while most data come from post-hoc analyses of trials including both manic and mixed patients. Improvement of manic symptoms in mixed episodes is similar to that seen in pure manic episodes and independent of baseline depressive features. The magnitude of response to manic symptoms' treatment probably exceeds that of depressive symptoms, which appear to resolve later. Valproate and carbamazepine are effective in acute mixed episodes, but the efficacy of lithium appears questionable. Atypical antipsychotic monotherapy improves both manic and depressive symptoms. Mood-stabilizer-atypical antipsychotic combination increases this effect. Atypical antipsychotic-antidepressant combination against acute mixed depression does not increase the risk for mania, although its superior efficacy vs. atypical antipsychotic monotherapy cannot be supported by current data. As regards prophylaxis, atypical antipsychotic monotherapy is associated with a lower incidence of and a longer time to relapse of any kind. The augmentation of lithium or divalproex with atypical antipsychotics increases prophylactic efficacy. Lithium or divalproex monotherapy have not been associated with significant prophylactic benefits following mixed mania. New, randomized prospective trials involving homogeneous cohorts of mixed bipolar patients are needed in order to delineate the appropriate pharmacological treatment of mixed states.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145711001817

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. APA (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry 159 (Suppl.), 1-50.

Cited by

Sorted by citations

Authors
Fountoulakis, K. N., Kontis, D., Gonda, X., Siamouli, M., & Yatham, L. N.
Affiliations
  • Asklepios Klinik Langen (DE)
  • University of British Columbia (CA)
Corresponding author
Kontis, Dimitrios
Venue
The International Journal of Neuropsychopharmacology
Published
2012-01-05
Volume
15
Issue
07
Pages
1015-1026
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2093726998
Cited by
68
References
69
Citations by year
2025: 2 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 2 · 2018: 4 · 2017: 6 · 2016: 10 · 2015: 6 · 2014: 13 · 2013: 8 · 2012: 1
FWCI
1.21
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Pfizer Foundation
  • Cilag
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
bipolar disorder, mixed mania, mixed depression, manic symptoms, depressive symptoms, valproic acid, carbamazepine, lithium, atypical antipsychotics, mood stabilizers, antidepressants, prophylaxis, relapse prevention, treatment response
MeSH terms
Antidepressive Agents, Bipolar Disorder, Humans, Antipsychotic Agents, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review